Articles related to HEART ATTACK/MYOCARDIAL INFARCTION

A network meta-analysis of 24 trials (16,371 patients) found complete revascularization in myocardial infarction with multivessel disease reduced all-cause mortality by 15% compared to culprit-only revascularization, suggesting potential improved outcomes for this population.

A 70-year-old diabetic woman presented with epigastric pain and was diagnosed with a transmural anteroseptal myocardial infarction complicated by a left ventricular thrombus. Using an image, this case reinforces the critical importance of recognizing and managing late-presenting myocardial infarction.

The recent trial assessing CSL112’s role in enhancing cholesterol efflux capacity showed no significant reduction in cardiovascular events over one year among patients post-acute myocardial infarction, maintaining a safety profile consistent with placebo.

In a multinational study involving more than 1,500 patients with complex cardiac profiles, findings revealed no statistically significant difference in the primary outcome of death, myocardial infarction, or unplanned revascularization between FFR-guided complete revascularization and culprit-lesion-only PCI over nearly five years of follow-up.

In a recent randomized, multicenter trial, the use of a microaxial flow pump in addition to standard care resulted in a mortality reduction at 180 days among STEMI patients with cardiogenic shock, with a significant hazard ratio of 0.74.

In a rigorous study involving 6,522 patients, empagliflozin, when administered post-acute myocardial infarction, demonstrated a reduction in first hospitalizations due to heart failure, although it did not significantly alter overall survival rates compared to placebo.